Symbols / CTMX
CTMX Chart
About
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 921.73M |
| Enterprise Value | 783.70M | Income | 28.02M | Sales | 113.63M |
| Book/sh | 0.65 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 119 | IPO | — |
| P/E | 18.13 | Forward P/E | -14.80 | PEG | — |
| P/S | 8.11 | P/B | 8.36 | P/C | — |
| EV/EBITDA | 31.95 | EV/Sales | 6.90 | Quick Ratio | 3.54 |
| Current Ratio | 3.64 | Debt/Eq | 5.21 | LT Debt/Eq | — |
| EPS (ttm) | 0.30 | EPS next Y | -0.37 | EPS Growth | — |
| Revenue Growth | -82.20% | Earnings | 2026-03-05 | ROA | 9.78% |
| ROE | 66.76% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -264.43% | Profit Margin | 24.66% | Shs Outstand | 169.44M |
| Shs Float | 122.81M | Short Float | 9.06% | Short Ratio | 4.71 |
| Short Interest | — | 52W High | 6.35 | 52W Low | 0.40 |
| Beta | 2.43 | Avg Volume | 3.02M | Volume | 1.83M |
| Target Price | $9.00 | Recom | None | Prev Close | $5.58 |
| Price | $5.44 | Change | -2.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$5.44
Latest analyst target
3. DCF / Fair value
$-5.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.44
Low
$6.00
High
$10.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-04 | main | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2026-02-04 | main | Barclays | Overweight → Overweight | $10 |
| 2026-01-20 | main | Barclays | Overweight → Overweight | $8 |
| 2026-01-20 | init | Guggenheim | — → Buy | $10 |
| 2026-01-20 | main | Piper Sandler | Overweight → Overweight | $10 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-10-21 | main | Barclays | Overweight → Overweight | $6 |
| 2025-09-22 | init | Cantor Fitzgerald | — → Overweight | $6 |
| 2025-07-31 | init | Oppenheimer | — → Outperform | $7 |
| 2025-05-20 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-15 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2025-05-15 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-04-14 | main | Piper Sandler | Overweight → Overweight | $3 |
| 2025-03-07 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-07 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-11 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-09-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-27 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-05-28 | up | Piper Sandler | Neutral → Overweight | $4 |
- $CTMX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- CytomX Therapeutics' (NASDAQ:CTMX) investors will be pleased with their incredible 402% return over the last year - Yahoo Finance Fri, 16 Jan 2026 08
- New colorectal and melanoma drug trials expected to yield results in 2026 - Stock Titan hu, 08 Jan 2026 08
- Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st Fri, 23 Jan 2026 08
- Can CytomX Therapeutics Stock Hold Up When Markets Turn? - Trefis Sat, 20 Dec 2025 08
- CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling - Seeking Alpha Mon, 15 Dec 2025 08
- CytomX Therapeutics (CTMX) Price Target Increased by 20.20% to 8.67 - Nasdaq Wed, 04 Feb 2026 08
- $CTMX stock is up 31% today. Here's what we see in our data. - Quiver Quantitative Fri, 16 Jan 2026 08
- CytomX (NASDAQ: CTMX) reports $143.6M cash; runway to Q2 2027, CX-2051 on track - Stock Titan hu, 06 Nov 2025 08
- Downgrade: Here's How Analysts See CytomX Therapeutics, Inc. (NASDAQ:CTMX) Performing In The Near Term - Yahoo Finance hu, 13 Nov 2025 08
- CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible - Seeking Alpha Mon, 13 Oct 2025 07
- CytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last year - Yahoo Finance Sun, 03 Aug 2025 07
- CytomX Therapeutics (NASDAQ: CTMX) joins Evercore, Piper Sandler healthcare investor conferences in December - Stock Titan ue, 25 Nov 2025 08
- CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate - Yahoo Finance Fri, 25 Jul 2025 07
- CytomX Therapeutics (Nasdaq: CTMX) to present at Jefferies London Nov 20 at 9:00 a.m. GMT - Stock Titan hu, 13 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 210000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCARTHY SEAN A. | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | CHU YU-WAYE | Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 90000 | — | — | Stock Award(Grant) at price 0.00 per share. | OGDEN CHRISTOPHER | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 60000 | — | — | Stock Award(Grant) at price 0.00 per share. | BELVIN MARCIA | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | LESTER RACHAEL | Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 101793 | 461906.0 | — | Sale at price 4.54 per share. | MCCARTHY SEAN A. | Chief Executive Officer | — | 2025-11-06 00:00:00 | D |
| 6 | 55511 | 149264.0 | — | Sale at price 2.69 per share. | MCCARTHY SEAN A. | Chief Executive Officer | — | 2025-06-16 00:00:00 | D |
| 7 | 12255 | 33381.0 | — | Sale at price 2.69 - 2.95 per share. | OGDEN CHRISTOPHER | Chief Financial Officer | — | 2025-06-16 00:00:00 | D |
| 8 | 13884 | 37334.0 | — | Sale at price 2.69 per share. | BELVIN MARCIA | Officer | — | 2025-06-16 00:00:00 | D |
| 9 | 150000 | nan | — | — | MCCARTHY SEAN A. | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | 26.76M | -4.31M | -98.89M | -113.34M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 31.87M | -569.00K | -99.32M | -115.87M |
| ReconciledDepreciation | 1.77M | 2.17M | 2.44M | 2.71M |
| EBITDA | 26.76M | -4.31M | -98.89M | -113.34M |
| EBIT | 25.00M | -6.48M | -101.33M | -116.04M |
| NetInterestIncome | 7.14M | 9.84M | 1.68M | 255.00K |
| InterestIncome | 7.14M | 9.84M | 1.68M | 255.00K |
| NormalizedIncome | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 31.87M | -569.00K | -99.32M | -115.87M |
| TotalExpenses | 113.11M | 107.70M | 154.50M | 153.35M |
| TotalOperatingIncomeAsReported | 25.00M | -6.48M | -101.33M | -116.04M |
| DilutedAverageShares | 84.75M | 73.81M | 65.74M | 64.15M |
| BasicAverageShares | 84.44M | 73.81M | 65.74M | 64.15M |
| DilutedEPS | 0.38 | -0.01 | -1.51 | -1.30 |
| BasicEPS | 0.38 | -0.01 | -1.51 | -1.30 |
| DilutedNIAvailtoComStockholders | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeCommonStockholders | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncome | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeIncludingNoncontrollingInterests | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeContinuousOperations | 31.87M | -569.00K | -99.32M | -115.87M |
| TaxProvision | 224.00K | 3.89M | 0.00 | 0.00 |
| PretaxIncome | 32.09M | 3.32M | -99.32M | -115.87M |
| OtherIncomeExpense | -38.00K | -30.00K | 340.00K | -83.00K |
| OtherNonOperatingIncomeExpenses | -38.00K | -30.00K | 340.00K | -83.00K |
| NetNonOperatingInterestIncomeExpense | 7.14M | 9.84M | 1.68M | 255.00K |
| InterestIncomeNonOperating | 7.14M | 9.84M | 1.68M | 255.00K |
| OperatingIncome | 25.00M | -6.48M | -101.33M | -116.04M |
| OperatingExpense | 113.11M | 107.70M | 154.50M | 153.35M |
| ResearchAndDevelopment | 83.38M | 77.68M | 111.65M | 114.19M |
| SellingGeneralAndAdministration | 29.73M | 30.02M | 42.85M | 39.16M |
| GeneralAndAdministrativeExpense | 29.73M | 30.02M | 42.85M | 39.16M |
| OtherGandA | 29.73M | 30.02M | 42.85M | 39.16M |
| TotalRevenue | 138.10M | 101.21M | 53.16M | 37.31M |
| OperatingRevenue | 138.10M | 101.21M | 53.16M | 37.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 80.10M | 67.31M | 66.23M | 65.39M |
| ShareIssued | 80.10M | 67.31M | 66.23M | 65.39M |
| TotalDebt | 9.38M | 13.97M | 18.06M | 21.67M |
| TangibleBookValue | -1.99M | -49.12M | -87.58M | -2.43M |
| InvestedCapital | -456.00K | -47.45M | -85.75M | -459.00K |
| WorkingCapital | 21.53M | 27.02M | 84.49M | 232.43M |
| NetTangibleAssets | -1.99M | -49.12M | -87.58M | -2.43M |
| CapitalLeaseObligations | 9.38M | 13.97M | 18.06M | 21.67M |
| CommonStockEquity | -456.00K | -47.45M | -85.75M | -459.00K |
| TotalCapitalization | -456.00K | -47.45M | -85.75M | -459.00K |
| TotalEquityGrossMinorityInterest | -456.00K | -47.45M | -85.75M | -459.00K |
| StockholdersEquity | -456.00K | -47.45M | -85.75M | -459.00K |
| GainsLossesNotAffectingRetainedEarnings | 27.00K | 95.00K | 10.00K | -242.00K |
| OtherEquityAdjustments | 27.00K | 95.00K | 10.00K | -242.00K |
| RetainedEarnings | -691.58M | -723.45M | -722.88M | -623.56M |
| AdditionalPaidInCapital | 691.10M | 675.90M | 637.12M | 623.34M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 1.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 120.99M | 249.24M | 346.64M | 339.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.22M | 93.33M | 194.03M | 262.00M |
| OtherNonCurrentLiabilities | 4.12M | 3.89M | ||
| NonCurrentDeferredLiabilities | 26.86M | 80.05M | 180.06M | 243.94M |
| NonCurrentDeferredRevenue | 26.86M | 80.05M | 180.06M | 243.94M |
| LongTermDebtAndCapitalLeaseObligation | 4.24M | 9.38M | 13.97M | 18.06M |
| LongTermCapitalLeaseObligation | 4.24M | 9.38M | 13.97M | 18.06M |
| CurrentLiabilities | 85.77M | 155.91M | 152.61M | 77.87M |
| CurrentDeferredLiabilities | 67.20M | 132.27M | 121.27M | 40.82M |
| CurrentDeferredRevenue | 67.20M | 132.27M | 121.27M | 40.82M |
| CurrentDebtAndCapitalLeaseObligation | 5.14M | 4.59M | 4.08M | 3.62M |
| CurrentCapitalLeaseObligation | 5.14M | 4.59M | 4.08M | 3.62M |
| PayablesAndAccruedExpenses | 13.43M | 19.06M | 27.26M | 33.44M |
| CurrentAccruedExpenses | 12.34M | 17.60M | 24.45M | 30.62M |
| Payables | 1.09M | 1.46M | 2.81M | 2.82M |
| AccountsPayable | 1.09M | 1.46M | 2.81M | 2.82M |
| TotalAssets | 120.53M | 201.79M | 260.89M | 339.41M |
| TotalNonCurrentAssets | 13.23M | 18.86M | 23.79M | 29.11M |
| OtherNonCurrentAssets | 1.09M | 1.00M | 944.00K | 1.82M |
| GoodwillAndOtherIntangibleAssets | 1.53M | 1.68M | 1.82M | 1.97M |
| OtherIntangibleAssets | 583.00K | 729.00K | 875.00K | 1.02M |
| Goodwill | 949.00K | 949.00K | 949.00K | 949.00K |
| NetPPE | 10.60M | 16.18M | 21.02M | 25.32M |
| AccumulatedDepreciation | -16.23M | -14.69M | -14.37M | -13.83M |
| GrossPPE | 26.83M | 30.87M | 35.39M | 39.15M |
| Leases | 2.00M | 1.98M | 1.74M | 1.74M |
| ConstructionInProgress | 0.00 | 368.00K | 705.00K | 308.00K |
| OtherProperties | 8.14M | 12.22M | 15.95M | 19.36M |
| MachineryFurnitureEquipment | 16.69M | 16.30M | 17.00M | 17.75M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 107.31M | 182.94M | 237.10M | 310.30M |
| OtherCurrentAssets | 3.58M | 5.00M | 7.47M | 4.29M |
| PrepaidAssets | 4.29M | |||
| Receivables | 3.10M | 3.43M | 35.99M | 790.00K |
| AccountsReceivable | 3.10M | 3.43M | 35.99M | 790.00K |
| CashCashEquivalentsAndShortTermInvestments | 100.62M | 174.51M | 193.65M | 305.23M |
| OtherShortTermInvestments | 62.57M | 157.34M | 0.00 | 99.70M |
| CashAndCashEquivalents | 38.05M | 17.17M | 193.65M | 205.53M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -86.54M | -56.88M | -112.53M | -120.64M |
| IssuanceOfCapitalStock | 6.91M | 0.00 | 107.71M | |
| CapitalExpenditure | -310.00K | -840.00K | -1.74M | -1.61M |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 39.08M | 18.09M | 194.57M | 206.45M |
| BeginningCashPosition | 18.09M | 194.57M | 206.45M | 192.78M |
| ChangesInCash | 20.99M | -176.48M | -11.88M | 13.67M |
| FinancingCashFlow | 7.52M | 30.23M | 648.00K | 110.21M |
| CashFlowFromContinuingFinancingActivities | 7.52M | 30.23M | 648.00K | 110.21M |
| ProceedsFromStockOptionExercised | 613.00K | 30.23M | 648.00K | 2.50M |
| NetCommonStockIssuance | 6.91M | 0.00 | 107.71M | |
| CommonStockIssuance | 6.91M | 0.00 | 107.71M | |
| InvestingCashFlow | 99.70M | -150.67M | 98.26M | 22.49M |
| CashFlowFromContinuingInvestingActivities | 99.70M | -150.67M | 98.26M | 22.49M |
| NetInvestmentPurchaseAndSale | 100.01M | -149.83M | 100.00M | 24.10M |
| SaleOfInvestment | 255.50M | 275.00M | 100.00M | 124.00M |
| PurchaseOfInvestment | -155.49M | -424.83M | 0.00 | -99.90M |
| NetPPEPurchaseAndSale | -310.00K | -840.00K | -1.74M | -1.61M |
| PurchaseOfPPE | -310.00K | -840.00K | -1.74M | -1.61M |
| OperatingCashFlow | -86.23M | -56.03M | -110.79M | -119.03M |
| CashFlowFromContinuingOperatingActivities | -86.23M | -56.03M | -110.79M | -119.03M |
| ChangeInWorkingCapital | -126.42M | -62.51M | -30.65M | -22.44M |
| ChangeInOtherWorkingCapital | -118.25M | -89.01M | 16.57M | -33.95M |
| ChangeInOtherCurrentAssets | -56.00K | 874.00K | 1.27M | |
| ChangeInPayablesAndAccruedExpense | -9.93M | -8.47M | -9.72M | 7.42M |
| ChangeInAccruedExpense | -9.63M | -7.04M | -9.78M | 7.56M |
| ChangeInPayable | -297.00K | -1.43M | 68.00K | -139.00K |
| ChangeInAccountPayable | -297.00K | -1.43M | 68.00K | -139.00K |
| ChangeInPrepaidAssets | 1.43M | 2.42M | -3.18M | 2.81M |
| ChangeInReceivables | 329.00K | 32.55M | -35.20M | 8.00K |
| ChangesInAccountReceivables | 329.00K | 32.55M | -35.20M | 8.00K |
| OtherNonCashItems | 4.08M | 3.73M | 3.41M | 3.13M |
| StockBasedCompensation | 7.67M | 8.56M | 13.12M | 13.17M |
| AssetImpairmentCharge | 106.00K | 0.00 | 254.00K | 0.00 |
| AmortizationOfSecurities | -5.31M | -7.42M | -52.00K | 272.00K |
| DepreciationAmortizationDepletion | 1.77M | 2.17M | 2.44M | 2.71M |
| DepreciationAndAmortization | 1.77M | 2.17M | 2.44M | 2.71M |
| AmortizationCashFlow | 146.00K | 146.00K | 146.00K | 146.00K |
| AmortizationOfIntangibles | 146.00K | 146.00K | 146.00K | 146.00K |
| Depreciation | 1.62M | 2.03M | 2.30M | 2.56M |
| NetIncomeFromContinuingOperations | 31.87M | -569.00K | -99.32M | -115.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CTMX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|